Use of ibandronate in the prevention of skeletal events in metastatic breast cancer.

Therapeutics and Clinical Risk Management
Bianca Devitt, Sue-Anne McLachlan

Abstract

Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression. Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer. Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations. It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks. Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring. Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate.

Citations

Nov 20, 2009·Journal of Palliative Medicine·Eric E Prommer
Apr 11, 2015·Der Schmerz·S KoyR Sabatowski
Jan 19, 2011·Cancer Immunology, Immunotherapy : CII·Evangelos Terpos, Meletios A Dimopoulos
Mar 23, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Joaquim Bosch-BarreraCatherine Van Poznak
Apr 30, 2021·Cellular Oncology (Dordrecht)·Bikashita Kalita, Mohane Selvaraj Coumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2022 Meta ULC. All rights reserved